Please login to the form below

Not currently logged in
Email:
Password:

balugrastim

This page shows the latest balugrastim news and features for those working in and with pharma, biotech and healthcare.

EMA backs 15 new medicines for use in EU

EMA backs 15 new medicines for use in EU

tilmanocept) for the delineation and localisation of sentinel lymph nodes; and Teva's Egranli (balugrastim) to treat chemotherapy-induced neutropenia.

Latest news

  • Teva withdraws US filing for cancer biologic Teva withdraws US filing for cancer biologic

    FDA requests more data for balugrastim. Teva said this week it is "assessing its options" after withdrawing the US drug filing for long-acting white cell stimulator balugrastim. ... The FDA has agreed to work with Teva in designing any additional studies

  • Neulasta rival from Teva cleared in EU Neulasta rival from Teva cleared in EU

    Teva's biologics pipeline also includes reslizumab, a monoclonal antibody targeting interleukin-5 (IL-5) in phase III for moderate-to-severe asthma, and an albumin-fused G-CSF called balugrastim

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

How Far Do You Want To Go?
Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…...
"Fishbowl" Web Meeting for Internal POA Discussions: a Customer Story
Learn how our client successfully carried out a set of three virtual plan of action (POA) discussions, including one internal “Fishbowl” web meeting....
Whats the difference between patient engagement and patient experience?
We all talk a lot about patient engagement and patient experience. And sometimes, these terms are used interchangeably across the industry. But while they’re both important, they’re not the same....

Infographics